Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway
文献类型：期刊论文
| 作者 | Shao, Jialiang7,8; Zhu, Wencheng4; Ding, Yufeng5; Zhu, Hongwen6; Jing, Xiaoqian1; Yu, Hua7; Lu, Mujun5; Qiao, Yunbo7; Wang, Xiang8; Ai, Hua2,3 |
| 刊名 | CANCER LETTERS
 |
| 出版日期 | 2019 |
| 卷号 | 451页码:110-121 |
| ISSN号 | 0304-3835 |
| 关键词 | LIFR Phosphorylation Prostate cancer AKT |
| DOI | 10.1016/j.canlet.2019.02.042 |
| 通讯作者 | Zhu, Hongwen(zhw@simm.ac.cn) ; Qiao, Yunbo(ybqiao@gzhu.edu.cn) ; Wang, Xiang(drseanwang@163.com) ; Wang, Xiongjun(xjwang02@sibcb.ac.cn) |
| 英文摘要 | Prostate cancer (PCa) is the most common solid organ malignancy among men, outnumbering both lung and colorectal cancer, and it is the second leading cause of male tumor-related death in the United States due to high metastasis. Recently, leukemia inhibitory factor receptor (LIFR) has been found to play roles in multiple types of cancer. However, the roles of LIFR in the progression of PCa remain to be revealed. In this study, we found that LIFR plays an oncogenic role in PCa. The phosphorylation of LIFR at 51044 contributes to subsequent activation of the AKT pathway, inducing the expression of a series of proliferation and metastatic genes. Additionally, LIFR-S1044 is phosphorylated by ERK2 but not EFtKl. The signal intensity of pLIFR-S1044 and pAKT 5473 in PCa tissue displays a tight positive correlation. The ERK2/LIFR/AKT axis modulates PCa progression and offers a promising therapeutic and diagnostic target for PCa. |
| WOS关键词 | LEUKEMIA-INHIBITORY FACTOR ; FACTOR-RECEPTOR ; METASTASIS SUPPRESSOR ; INTERLEUKIN-6 FAMILY ; SOLUBLE FORM ; GROWTH ; CELLS ; IDENTIFICATION ; EXPRESSION ; CYTOKINES |
| 资助项目 | Hundred Talent Program of Guangzhou University ; National Natural Science Foundation of China[81570607] ; National Natural Science Foundation of China[81170697] ; Shanghai Shenkang Hospital Development Center Fund[16CR2003A] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| 出版者 | ELSEVIER IRELAND LTD |
| WOS记录号 | WOS:000464297000011 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/290100]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Zhu, Hongwen; Qiao, Yunbo; Wang, Xiang; Wang, Xiongjun |
| 作者单位 | 1.Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Surg, Shanghai 200025, Peoples R China 2.Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610065, Sichuan, Peoples R China 3.Sichuan Univ, West China Hosp, Dept Radiol, Chengdu 610065, Sichuan, Peoples R China 4.Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China 5.Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Urol & Androl, Shanghai 200001, Peoples R China 6.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 7.Guangzhou Univ, Sch Life Sci, Precise Genome Engn Ctr, Guangzhou 510006, Guangdong, Peoples R China 8.Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Urol, Shanghai 200080, Peoples R China |
| 推荐引用方式 GB/T 7714 | Shao, Jialiang,Zhu, Wencheng,Ding, Yufeng,et al. Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway[J]. CANCER LETTERS,2019,451:110-121. |
| APA | Shao, Jialiang.,Zhu, Wencheng.,Ding, Yufeng.,Zhu, Hongwen.,Jing, Xiaoqian.,...&Wang, Xiongjun.(2019).Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway.CANCER LETTERS,451,110-121. |
| MLA | Shao, Jialiang,et al."Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway".CANCER LETTERS 451(2019):110-121. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。